bl-b01d1
biokin pharma
['bl-b01d1', 'nsclc', 'sclc']
wow! bl-b01d1 the first bispecific antibody-drug conjugate targeting egfr &amp; her3. orr of 63% in pretreated egfr mutant nsclc. #asco23 #asco2023 #asco 
A dedicated conference for oncology held under the theme "Access. Educate. Collaborate"